| Erdafitinib studied in …STUDIED_INderived26 of 26show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 26 trials list this drug (13 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02365597Phase 2 · active not recruiting An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer · 26 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03390504Phase 3 · active not recruiting A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations · 26 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03210714Phase 2 · active not recruiting Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) · 26 trials list this drug (13 active) | — | — | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor,Hepatoblastoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04963153Phase 1 · active not recruiting Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · 26 trials list this drug (13 active) | — | — | Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04083976Phase 2 · completed A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations · 26 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06308822Phase 2 · active not recruiting Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) · 26 trials list this drug (13 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04917809Phase 2 · active not recruiting A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer · 26 trials list this drug (13 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03473743Phase 1/Phase 2 · active not recruiting A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer · 26 trials list this drug (13 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05859334Phase 2 · active not recruiting Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment · 26 trials list this drug (13 active) | — | — | Glioma,WHO Grade 2 Glioma,WHO Grade 3 Glioma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · 26 trials list this drug (13 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06351371Phase 2 · active not recruiting Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) · 26 trials list this drug (13 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06204614early Phase 1 · enrolling by invitation Drug Screening Using IMD in Bladder Cancer · 26 trials list this drug (13 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04172675Phase 2 · completed A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) · 26 trials list this drug (13 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04754425Phase 2 · terminated Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer · 26 trials list this drug (13 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Prostate Small Cell Neuroendocrine Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564416Phase 2 · withdrawn Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial · 26 trials list this drug (13 active) | — | — | Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03825484approved for marketing Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options · 26 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03547037Phase 1 · completed A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers · 26 trials list this drug (13 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02699606Phase 2 · completed A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma · 26 trials list this drug (13 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03238196Phase 1 · completed Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer · 26 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328491NA · completed Erdafitinib in Metastatic Steroid-cell Ovarian Cancer · 26 trials list this drug (13 active) | — | — | Malignant Ovarian Neoplasm,Malignant Ovarian Steroid Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 26 trials list this drug (13 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03999515Phase 2 · terminated Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer · 26 trials list this drug (13 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Prostate Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03827850Phase 2 · terminated FGFR Inhibitor in FGFR Dysregulated Cancer · 26 trials list this drug (13 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05052372terminated Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib · 26 trials list this drug (13 active) | — | — | Transitional Cell Carcinoma,Urothelial Carcinoma,Bladder Urothelial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02952573Phase 2 · terminated Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement · 26 trials list this drug (13 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |